Moreover, the company has not provided statistical information (e.g., power to detect differences of a stated magnitude) for any of its randomized trials leading one to wonder if the trials were so underpowered that the company was uncomfortable sharing this information. Then there are the results from the failed randomized trials in 2nd-line NSCLC and 1st-line pancreatic cancer which have seemingly been ignored by the company. Finally, the development history of bavituximab suggests reluctance on Peregrine's part to test the drug in a well-powered study. The party is over for Peregrine, investors are losing patience and it's time to move on.
most likely over, by now there should be a definitive and obvious answer if bavi works. the fact that retail shareholders have to come up with their own theories is a very bad sign.
but hey, there's still that exciting HCV data and the promising sub-populations in the pancreatic data!!!